Login to Your Account



CBLI in Damage Control Mode After Surprise BARDA Rejection

By Catherine Shaffer
Staff Writer

Thursday, April 5, 2012
For Cleveland BioLabs Inc., of Buffalo, N.Y., the question of the day was phrased by its vice president of pharmaceutical development, Ed Venkat, who asked, "Why did BARDA reject our white paper proposals?"

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription